Regulatory
FDA Approves an All-Oral Combo That Doubles Progression-Free Time in a Breast Cancer Subtype
Lilly’s Inluriyo plus Verzenio is now cleared for ER-positive, HER2-negative breast cancer with an ESR1 mutation — a resistance driver — after a trial showed switching to the combo doubled how long the cancer stayed in check.